Literature DB >> 19935868

Molecular disruption of oncogenic signal transducer and activator of transcription 3 (STAT3) protein.

Steven Fletcher1, Joel A Drewry, Vijay M Shahani, Brent D G Page, Patrick T Gunning.   

Abstract

Signal transducer and activator of transcription protein 3 (STAT3) is a latent cytosolic transcription factor that is widely recognized as being a master regulator of the cellular functions that lead to the cancer phenotype. Constitutively activated STAT3 protein activity is routinely observed in human cancers, promoting uncontrolled cell proliferation and suppressing apoptosis. Until relatively recently, inhibition of STAT3 transcriptional activity was achieved indirectly via suppression of upstream kinase activators and extracellular cytokine and (or) growth factor stimuli. However, activated STAT3 forms transcriptionally functional STAT3-STAT3 dimers, providing a valid juncture for targeted downstream molecular inhibition. STAT3's prominent role in cancer has seen a decade of innovative and novel approaches to targeting constitutively active STAT3 protein-protein complexes. This mini-review outlines the progress made towards identifying molecular agents capable of silencing aberrant STAT3 signalling through the disruption of STAT3 complexation events.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19935868     DOI: 10.1139/o09-044

Source DB:  PubMed          Journal:  Biochem Cell Biol        ISSN: 0829-8211            Impact factor:   3.626


  27 in total

Review 1.  Oncogenic role and therapeutic target of leptin signaling in breast cancer and cancer stem cells.

Authors:  Shanchun Guo; Mingli Liu; Guangdi Wang; Marta Torroella-Kouri; Ruben R Gonzalez-Perez
Journal:  Biochim Biophys Acta       Date:  2012-01-24

Review 2.  NF-κB and STAT3 - key players in liver inflammation and cancer.

Authors:  Guobin He; Michael Karin
Journal:  Cell Res       Date:  2010-12-28       Impact factor: 25.617

3.  Benzoxathiol derivative BOT-4-one suppresses L540 lymphoma cell survival and proliferation via inhibition of JAK3/STAT3 signaling.

Authors:  Byung Hak Kim; Yun Sook Min; Jung Sook Choi; Gyeong Hun Baeg; Young Soo Kim; Jong Wook Shin; Tae Yoon Kim; Sang Kyu Ye
Journal:  Exp Mol Med       Date:  2011-05-31       Impact factor: 8.718

4.  STAT3 inhibition reduces toxicity of oncolytic VSV and provides a potentially synergistic combination therapy for hepatocellular carcinoma.

Authors:  S Marozin; J Altomonte; K A Muñoz-Álvarez; A Rizzani; E N De Toni; W E Thasler; R M Schmid; O Ebert
Journal:  Cancer Gene Ther       Date:  2015-05-01       Impact factor: 5.987

5.  High-content pSTAT3/1 imaging assays to screen for selective inhibitors of STAT3 pathway activation in head and neck cancer cell lines.

Authors:  Paul A Johnston; Malabika Sen; Yun Hua; Daniel Camarco; Tong Ying Shun; John S Lazo; Jennifer R Grandis
Journal:  Assay Drug Dev Technol       Date:  2013-10-15       Impact factor: 1.738

6.  Antagonism of the Stat3-Stat3 protein dimer with salicylic acid based small molecules.

Authors:  Steven Fletcher; Brent D G Page; Xialoei Zhang; Peibin Yue; Zhi Hua Li; Sumaiya Sharmeen; Jagdeep Singh; Wei Zhao; Aaron D Schimmer; Suzanne Trudel; James Turkson; Patrick T Gunning
Journal:  ChemMedChem       Date:  2011-05-25       Impact factor: 3.466

Review 7.  STAT3 signaling: anticancer strategies and challenges.

Authors:  Paul A Johnston; Jennifer R Grandis
Journal:  Mol Interv       Date:  2011-02

8.  Drug transporter-independent liver cancer cell killing by a marine steroid methyl spongoate via apoptosis induction.

Authors:  Yi Jiang; Ze-Hong Miao; Lei Xu; Bing Yu; Jing-Xu Gong; Lin-Jiang Tong; Yi Chen; Zhao-Li Zhou; Hong-Chun Liu; Yi Wang; Yue-Wei Guo; Jian Ding
Journal:  J Biol Chem       Date:  2011-06-09       Impact factor: 5.157

9.  NKp46 identifies an NKT cell subset susceptible to leukemic transformation in mouse and human.

Authors:  Jianhua Yu; Takeki Mitsui; Min Wei; Hsiaoyin Mao; Jonathan P Butchar; Mithun Vinod Shah; Jianying Zhang; Anjali Mishra; Christopher Alvarez-Breckenridge; Xingluo Liu; Shujun Liu; Akihiko Yokohama; Rossana Trotta; Guido Marcucci; Don M Benson; Thomas P Loughran; Susheela Tridandapani; Michael A Caligiuri
Journal:  J Clin Invest       Date:  2011-04       Impact factor: 14.808

10.  Design, synthesis, and in vitro characterization of novel hybrid peptidomimetic inhibitors of STAT3 protein.

Authors:  Vijay M Shahani; Peibin Yue; Steven Fletcher; Sumaiya Sharmeen; Mahadeo A Sukhai; Diana P Luu; Xiaolei Zhang; Hong Sun; Wei Zhao; Aaron D Schimmer; James Turkson; Patrick T Gunning
Journal:  Bioorg Med Chem       Date:  2010-12-09       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.